Inflammatory Markers of CRP, IL6, TNFα, and Soluble TNFR2 and the Risk of Ovarian Cancer: A Meta-analysis of Prospective Studies

Background: There has been growing evidence showing that inflammatory markers play an important role in the development of ovarian cancer. We conducted a meta-analysis on the associations between circulating levels of C-reactive protein (CRP), interleukin 6 (IL6), tumor necrosis factor α (TNFα), and soluble TNFα receptor 2 (TNFR2), and the risk of ovarian cancer. Methods: A systematic search of PubMed and EMBASE up until January 19, 2016 was conducted to retrieve prospective studies. The summary risk estimates were pooled using random-effects models. The dose–response relationship was assessed using generalized least-squares trend estimation. Results: Seven nested case–control studies and one prospective cohort study were included in the review. For circulating CRP, women in the highest category had a significantly increased risk of ovarian cancer than women in the lowest category, with no significant between-study heterogeneity [pooled relative risk (RR) = 1.91; 95% confidence intervals (CI) 1.51–2.40; P < 0.001; I2 = 0.0%]. Influence analyses further supported this positive association. A positive dose–response relationship was also observed (pooled RR = 1.15; 95% CI, 1.03–1.30 per 5 mg/L of CRP). Publication bias was found. However, the association persisted after correction using the trim-and-fill method. No significant association was observed for circulating IL6, TNFα, and soluble TNFR2. Conclusion: This meta-analysis provides evidence that elevated levels of CRP, but not circulating IL6, TNFα, or soluble TNFR2, are significantly associated with an increased risk of ovarian cancer. Impact: These results suggest that circulating CRP may play a role in the etiology of ovarian cancer. Cancer Epidemiol Biomarkers Prev; 25(8); 1231–9. ©2016 AACR.

[1]  F. Camacho,et al.  Analgesic medication use and risk of epithelial ovarian cancer in African American women , 2016, British Journal of Cancer.

[2]  D. Greenwood,et al.  Circulating C-Reactive Protein and Breast Cancer Risk—Systematic Literature Review and Meta-analysis of Prospective Cohort Studies , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[3]  I. Gram,et al.  Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[4]  P. Hartge,et al.  Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. , 2014, Gynecologic oncology.

[5]  Ying Zhang,et al.  CRP 1059 G/C and 1846G/A polymorphisms and cancer risk: a meta-analysis of 26,634 subjects. , 2014, Clinics and research in hepatology and gastroenterology.

[6]  M. Pike,et al.  Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. , 2014, Journal of the National Cancer Institute.

[7]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[8]  P. Ridker,et al.  A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor α receptor 2 levels and risk of ovarian cancer. , 2013, American journal of epidemiology.

[9]  S. Friis,et al.  Nonsteroidal anti‐inflammatory drugs and risk of ovarian cancer: systematic review and meta‐analysis of observational studies , 2013, Acta obstetricia et gynecologica Scandinavica.

[10]  Jacques Ferlay,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .

[11]  Xiaolei Zhang,et al.  Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. , 2012, Cytokine.

[12]  C. Madeddu,et al.  Inflammation and ovarian cancer. , 2012, Cytokine.

[13]  M. Lehtinen,et al.  Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Vittorio Krogh,et al.  Circulating Inflammation Markers and Risk of Epithelial Ovarian Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[15]  Richard D Riley,et al.  Interpretation of random effects meta-analyses , 2011, BMJ : British Medical Journal.

[16]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[17]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[18]  S. Bojesen,et al.  Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Berrino,et al.  C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy) , 2009, Cancer Causes & Control.

[20]  Anil K Sood,et al.  Early events in the pathogenesis of epithelial ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Brinton,et al.  C-Reactive Protein Concentrations and Subsequent Ovarian Cancer Risk , 2007, Obstetrics and gynecology.

[22]  T. Hagemann,et al.  The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. , 2007, Cancer research.

[23]  J. Ferlay,et al.  Worldwide burden of gynaecological cancer: the size of the problem. , 2006, Best practice & research. Clinical obstetrics & gynaecology.

[24]  A. Trichopoulou,et al.  Plasma C-Reactive Protein and Risk of Cancer: A Prospective Study from Greece , 2006, Cancer Epidemiology Biomarkers & Prevention.

[25]  J. Manson,et al.  Low-Dose Aspirin in the Primary Prevention of Cancer: The Women’s Health Study: A Randomized Controlled Trial , 2005, JAMA.

[26]  P. Schwartz Diagnosis and treatment of epithelial ovarian cancer. , 2003, Minerva ginecologica.

[27]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[28]  R. Tweedie,et al.  A Nonparametric “Trim and Fill” Method of Accounting for Publication Bias in Meta-Analysis , 2000 .

[29]  R. Ness,et al.  Possible role of ovarian epithelial inflammation in ovarian cancer. , 1999, Journal of the National Cancer Institute.

[30]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[31]  G. Mantovani,et al.  High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. , 1998, Gynecologic oncology.

[32]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[33]  G. Mantovani,et al.  Preovulatory human follicular fluid in vitro inhibits interleukin (IL)-1 alpha, IL-2, and production and expression of p55 chain IL-2 receptor of lymphomonocytes. , 1994, Fertility and sterility.

[34]  L. Twiggs,et al.  Serum and ascitic fluid levels of interleukin‐1, interleukin‐6, and tumor necrosis factor‐alpha in patients with ovarian epithelial cancer , 1993, Cancer.

[35]  S. Greenland,et al.  Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. , 1992, American journal of epidemiology.

[36]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[37]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[38]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.